Novel Lipids Targets in the Era of Metabolic Syndrome

摘要: During the last decades, prevalence of obesity, diabetes mellitus and metabolic syndrome (MetS) has dramatically risen in developed countries. A further increase MetS can be anticipated because projections a greater obesity future. Albeit cardiovascular (CV) risk patients with been considered high, large proportion these present normal low-density lipoprotein-cholesterol (LDL-C) levels. Conversely, often display high levels apolipoprotein B-100 (apoB), triglycerides (TG) non-high-density (non-HDL-C). Among routine lipoprotein assessment, use non-HDL-C shown several advantages over LDL-C, particularly presence hypertriglyceridaemia. Non-HDL-C is combined measurement (a), small dense LDL-C (sd-LDL-C), chilomicron remnants, intermediate-density lipoproteins. Several studies have that strong predictor subclinical atherosclerosis CV events as well reasonable surrogate apoB measurement. Moreover, current evidence supporting accurately predicts major even TG values. However, recommendations suggest only when exceeds 200 mg/dL, recommending primary target therapy all other conditions. These definitions contrast finding MetS, high-risk Therefore, redefinition needed also view an increased insulin resistance, abdominal diabetes.